Clinical Trial Update: Evaluating the Safety and Immune Response to Two Doses of a Dengue Virus Vaccine Administered 12 Months Apart [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluated the safety and immune response of a dengue virus vaccine given in two doses 12 months apart. The study status is COMPLETED.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dengue

Drugs mentioned

• Dengue virus vaccine (investigational)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Dengue | Phase 1 | Status: COMPLETED